



Attorney Docket No.: 6169.200-US

PATENT

RECEIVED  
OCT 24 2001  
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Liselotte Bjerre Knudsen

Serial No.: 09/800,541

Group Art Unit: To be assigned

Filed: March 7, 2001

Examiner: To be assigned

Confirmation No. 4130

For: Lowering Serum Lipids

CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)

Commissioner for Patents  
Washington, DC 20231

Sir:

I hereby certify that the attached correspondence comprising:

1. Supplemental Information Disclosure Statement
2. Form PTO-1449
3. Copy of References

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents  
Washington, DC 20231

on October 16, 2001.

Carol McFarlane-Fishberg  
(name of person mailing paper)

Carol McFarlane Fishberg  
(signature of person mailing paper)



23650

PATENT TRADEMARK OFFICE



Attorney Docket No.: 6169.200-US

RECEIVED  
OCT 24 2001  
PATENT  
TECH CENTER 1600/2900

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Liselotte Bjerre Knudsen

Application No.: 09/800,541

Group Art Unit: To be assigned

Filed: March 7, 2001

Examiner: To be assigned

Confirmation No. 4130

For: Lowering Serum Lipids

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
Washington, DC 20231

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Supplemental Information Disclosure Statement shall not be construed as a representation that no other material references than those listed exist or that a search has been conducted.

The references are listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. A copy of the references is also enclosed.

The references are as follows:

1. WO 99/38501;
2. WO 00/66629;
3. Juntti-Berggren, M.D., Ph.D. et al., Diabetes Care, Vol. 19, pgs. 1200-1206 (1996);


4. Creutzfeldt, M.D., F.R.C.P. et al., Diabetes Care, Vol. 19, pgs. 580-586 (1996);
5. Toft-Nielsen, M.D. et al., Diabetes Care, Vol. 22, pgs. 1137-1143 (1999); and
6. Abstract of Kolterman et al., Diabetologia, Supplement 1, Vol. 43, pg. A189 (2000).

It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the Undersigned if there are any questions concerning this paper or the attached references.

The supplemental information disclosure statement submitted herewith is being filed before the mailing date of a first Office action on the merits. Therefore, no fee is due.

Respectfully submitted,

Date: October 16, 2001

  
\_\_\_\_\_  
Reza Green, Reg. No. 38,475  
Novo Nordisk of North America, Inc.  
405 Lexington Avenue, Suite 6400  
New York, NY 10174-6401  
(212) 867-0123



23650

PATENT TRADEMARK OFFICE